ProQR Therapeutics NV
NASDAQ:PRQR
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.35
4.49
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PRQR stock under the Base Case scenario is 2.42 USD. Compared to the current market price of 3.62 USD, ProQR Therapeutics NV is Overvalued by 33%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
ProQR Therapeutics NV
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PRQR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
ProQR Therapeutics NV
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
ProQR Therapeutics NV
Balance Sheet Decomposition
ProQR Therapeutics NV
Current Assets | 92.4m |
Cash & Short-Term Investments | 89.4m |
Receivables | 770k |
Other Current Assets | 2.2m |
Non-Current Assets | 14.4m |
PP&E | 14.4m |
Current Liabilities | 39.6m |
Accounts Payable | 31k |
Accrued Liabilities | 1.4m |
Other Current Liabilities | 38.2m |
Non-Current Liabilities | 42.2m |
Long-Term Debt | 11.5m |
Other Non-Current Liabilities | 30.7m |
Earnings Waterfall
ProQR Therapeutics NV
Revenue
|
21.3m
EUR
|
Operating Expenses
|
-48m
EUR
|
Operating Income
|
-26.7m
EUR
|
Other Expenses
|
2.7m
EUR
|
Net Income
|
-23.9m
EUR
|
Free Cash Flow Analysis
ProQR Therapeutics NV
EUR | |
Free Cash Flow | EUR |
PRQR Profitability Score
Profitability Due Diligence
ProQR Therapeutics NV's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
ProQR Therapeutics NV's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
PRQR Solvency Score
Solvency Due Diligence
ProQR Therapeutics NV's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
ProQR Therapeutics NV's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRQR Price Targets Summary
ProQR Therapeutics NV
According to Wall Street analysts, the average 1-year price target for PRQR is 6.83 USD with a low forecast of 2.17 USD and a high forecast of 14.7 USD.
Dividends
Current shareholder yield for PRQR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. The company is headquartered in Leiden, Zuid-Holland. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Contact
IPO
Employees
Officers
The intrinsic value of one PRQR stock under the Base Case scenario is 2.42 USD.
Compared to the current market price of 3.62 USD, ProQR Therapeutics NV is Overvalued by 33%.